Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Verrica Pharmaceuticals Inc (NQ: VRCA )

13.46 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 12, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Verrica Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
From GlobeNewswire News Releases
Last Week's Notable Insider Buys: PennyMac Financial, Republic Services And More
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. Insider buying can be... 
Tags Technology Market News Services
From Blogs - TalkMarkets
Last Week's Notable Insider Buys: PennyMac Financial, Republic Services And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Yet again, ... 
Tags omega healthcare investors PennyMac Financial Services Insider Trades
From Benzinga
Verrica Announces Election of Gary Goldenberg, MD, Verrica’s Chief Medical Officer, to Membership in the American Dermatological Association
From GlobeNewswire News Releases
Investors Snag VRCA Even Lower Than Its Secondary Stock Offering
Looking back to 2 days ago, Verrica Pharmaceuticals Inc (VRCA) priced a 2,033,899 share secondary stock offering at $14.75 per share. Buyers in that offering made a considerable investment into the... 
Tags Stocks
From Market News Video
The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ... 
Tags NVO HRMY Earnings
From Benzinga
Verrica Announces Pricing of Public Offering of Common Stock
From GlobeNewswire News Releases
Verrica Announces Proposed Public Offering of Common Stock
From GlobeNewswire News Releases
The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags SVRA CELC SRRA
From Benzinga
Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Commercialize VP-102 For Molluscum and Common Warts in Japan
Torii to make upfront payment of $11.5 million to Verrica in addition to other potential milestone payments of up to $58 million and, if marketed in Japan, tiered transfer price payments as a... 
From GlobeNewswire News Releases
The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags LGVN ALT CEMI
From Benzinga
Stocks That Hit 52-Week Highs On Thursday
On Thursday morning, 420 companies hit new 52-week highs. Significant Points: The largest company by market cap to ... 
Tags SAL USFD TPC
From Benzinga
The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ... 
Tags VRCA FDA OCUL
From Benzinga
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results
From GlobeNewswire News Releases
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference
From GlobeNewswire News Releases
Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference
From GlobeNewswire News Releases
Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
From GlobeNewswire News Releases
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags SGEN ARWR Offerings
From Benzinga
Stocks That Hit 52-Week Highs On Tuesday
On Tuesday, 596 companies set new 52-week highs. Intriguing Points: PayPal Holdings (NASDAQ:PYPL) was the ... 
Tags TTI VFF TTGT
From Benzinga
Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Confer
From GlobeNewswire News Releases
Biggest Price Target Changes For Thursday
Morgan Stanley lifted the price target for Paychex, Inc. (NASDAQ: PAYX) from $76 to $91. Paychex shares rose 0.2% to $94.55 in ... 
Tags Market News Price Target Small Cap
From Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Bellicum Pharmaceuticals (NASDAQ:BLCM) shares rose 9.91% to $4.1 during Wednesday's after-market session. Trading volume ... 
Tags IMAB Health Care CMPI
From Benzinga
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
From GlobeNewswire News Releases
Verrica Pharmaceuticals Announces Receipt of Final FDA Minutes Following Type A Meeting Regarding Resubmission of the NDA for VP-102 in Molluscum
- Verrica reaffirms expectation to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 - 
From GlobeNewswire News Releases
Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual London Healthcare Conference
From GlobeNewswire News Releases
Verrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts (CARE-1)
From GlobeNewswire News Releases
Verrica Pharmaceuticals Reports Third Quarter 2020 Financial Results
From GlobeNewswire News Releases
Analysts See 13% Gains Ahead For The Holdings of VHT
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Gore Range Capital Bolsters Advisory Board for Skin Health Investments
Gore Range Capital adds world-class advisory board members to new skin health venture capital fund 
From Business Wire News Releases
JAMA Dermatology Publishes Results from Verrica’s Two Pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients) Trials
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.